Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Thursday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of OGEN stock opened at $0.20 on Thursday. The stock’s fifty day moving average price is $0.21 and its two-hundred day moving average price is $0.28. The company has a market cap of $4.30 million, a PE ratio of -0.03 and a beta of 1.16. Oragenics has a fifty-two week low of $0.16 and a fifty-two week high of $3.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.